| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 04/14/2011 | US20110086846 Azaindazole Compounds As CCR1 Receptor Antagonists |
| 04/14/2011 | US20110086845 Compositions and Methods for Treating Neurodegenerating Diseases |
| 04/14/2011 | US20110086843 Thiazole Derivatives and Use Thereof |
| 04/14/2011 | US20110086839 Compounds |
| 04/14/2011 | US20110086838 Novel compounds as cannabinoid receptor ligands |
| 04/14/2011 | US20110086836 Substituted Phenylpiperidine Derivatives As Melanocortin-4 Receptor Modulators |
| 04/14/2011 | US20110086834 Alkynyl alcohols as kinase inhibitors |
| 04/14/2011 | US20110086833 Methods for treating spinal muscular atrophy |
| 04/14/2011 | US20110086832 Novel compounds as cannabinoid receptor ligands |
| 04/14/2011 | US20110086828 Treatment of alcohol abuse and alcoholism using modulators of neurosteroid binding sites on gabaa receptors |
| 04/14/2011 | US20110086818 Methods, compositions, and kits for treating pain and pruritus |
| 04/14/2011 | US20110086804 Treatment of parkinson's disease |
| 04/14/2011 | US20110086799 GnRH II Analogs and Uses Thereof in the Immune System |
| 04/14/2011 | US20110086795 Small peptide modulators of potassium channel trafficking |
| 04/14/2011 | US20110086105 Methods for identifying novel nucleic acid regulatory elements and compounds that affect the regulation |
| 04/14/2011 | US20110086099 Crystalline mesoporous oxide based materials useful for the fixation and controlled release of drugs |
| 04/14/2011 | US20110086096 Modified release 1- [ (3-hydroxy-adamant-1-ylamino)-acetyl] -pyrrolidine-2 (s) -carbonitrile formulation |
| 04/14/2011 | US20110086090 Vectors Containing the Max Gene |
| 04/14/2011 | US20110086086 Transdermal system for varenicline |
| 04/14/2011 | US20110086063 Vaccines for prevention and treatment of addiction |
| 04/14/2011 | US20110086057 OX40R Binding Agents |
| 04/14/2011 | US20110086050 Glycoprotein compositions |
| 04/14/2011 | US20110086046 Treatment of MS with goat serum |
| 04/14/2011 | US20110086036 Composition comprising vlp and amyloid beta peptide |
| 04/14/2011 | US20110086034 Nucleotide and protein sequences of nogo genes and methods based thereon |
| 04/14/2011 | US20110086011 Prevention or Treatment of Immune-Relevant Disease by Modification of Microfloral Populations |
| 04/14/2011 | US20110085985 Novel substituted azabenzoxazoles |
| 04/14/2011 | US20110085980 Cell cycle regulation and differentiation |
| 04/14/2011 | US20110085978 Novel quinolinylamide derivatives useful as modulators of dopamine and serotonin receptors |
| 04/14/2011 | DE102009049662A1 2,5-Disubstituierte 2H-Indazole als EP2-Rezeptor-Antagonisten 2,5-disubstituted 2H-indazoles as EP2-receptor antagonists |
| 04/14/2011 | CA2777209A1 Tricyclic and tetracyclic systems with activity on the central-nervous and vascular systems |
| 04/14/2011 | CA2777185A1 Use of rasagiline for the treatment of progressive supranuclear palsy |
| 04/14/2011 | CA2777096A1 Compositions and methods for the transport of therapeutic agents |
| 04/14/2011 | CA2776919A1 Nutraceutical composition that comprises extract of shilajit, folic acid, vitamin b12 and vitamin b6 and the use thereof for preventing and/or treating neurodegenerative diseases and/or the cognitive deterioration associated with cerebral ageing |
| 04/14/2011 | CA2776847A1 Pyrrolo [3,2 -e] [1,2,4] triazolo [1,5-a] pyrimidines derivatives as inhibitors of microglia activation |
| 04/14/2011 | CA2776844A1 Pyrrolo [3, 2 -e] [1,2,4] triazolo [1,5 -a] pyrimidines derivatives as inhibitors of microglia activation |
| 04/14/2011 | CA2776770A1 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders |
| 04/14/2011 | CA2776308A1 Purine derivatives useful as hsp90 inhibitors |
| 04/14/2011 | CA2774963A1 Compositions and methods comprising pediococcus for reducing at least one symptom associated with autism spectrum disease in a person diagnosed with an autism spectrum disease |
| 04/14/2011 | CA2774579A1 Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| 04/14/2011 | CA2773713A1 Novel trpa1 antagonists |
| 04/13/2011 | EP2309261A1 Methods for evaluating tissue morphogenesis and morphogenic activity |
| 04/13/2011 | EP2308963A2 System for processing lipoaspirate cells |
| 04/13/2011 | EP2308879A1 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors |
| 04/13/2011 | EP2308876A1 Aza-bicycloalkyl ethers and their use as alpha7-nAChR agonists |
| 04/13/2011 | EP2308875A1 Fused bicycloheterocycle substituted quinuclidine derivatives as .alpha.7 nAChR modulators |
| 04/13/2011 | EP2308873A1 Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
| 04/13/2011 | EP2308870A2 2-oxo-1-pyrrolidine deriatives, processes for preparing them and their uses |
| 04/13/2011 | EP2308869A1 Azole compound |
| 04/13/2011 | EP2308867A2 2-oxo-1-pyrrolidine deriatives, processes for preparing them and their uses |
| 04/13/2011 | EP2308861A1 Macrocyclic compounds useful as pharmaceuticals |
| 04/13/2011 | EP2308855A1 2,4-Diaminopyrimidine derivatives |
| 04/13/2011 | EP2308854A1 2,3,6-trisubstituted-4-pyrimidone derivatives |
| 04/13/2011 | EP2308852A1 5-ring heteroaromatic compounds and their use as binding partners for 5-HT5 receptors |
| 04/13/2011 | EP2308849A1 Indane-amine derivatives, their preparation and use as medicaments |
| 04/13/2011 | EP2308846A2 Caspase inhibitors and uses thereof |
| 04/13/2011 | EP2308845A2 Caspase inhibitors and uses thereof |
| 04/13/2011 | EP2308844A2 Caspase inhibitors and uses thereof |
| 04/13/2011 | EP2308842A1 Pharmaceutical compositions |
| 04/13/2011 | EP2308833A2 Cyclic protein tyrosine kinase inhibitors |
| 04/13/2011 | EP2308562A2 Azetidine ring compounds and drugs comprising the same |
| 04/13/2011 | EP2308511A1 Tablet quickly disintegrating in the oral cavity and method for producing the same |
| 04/13/2011 | EP2308510A1 Agent for regeneration and/or protection of nerves |
| 04/13/2011 | EP2308509A1 Inhibitor of analgesic tolerance |
| 04/13/2011 | EP2308493A1 Ameliorating or therapeutic agent for dyslipidemia |
| 04/13/2011 | EP2308486A1 Pufa supplements |
| 04/13/2011 | EP2308475A1 Matrix for sustained, invariant and independent release of active compounds |
| 04/13/2011 | EP2308474A1 Matrix for sustained, invariant and independent release of active compounds |
| 04/13/2011 | EP2308473A1 Pharmaceutical composition containing surface-coated microparticles |
| 04/13/2011 | EP2307546A1 Treatment of pain with gap junction modulation compounds |
| 04/13/2011 | EP2307438A2 Novel cholest-4-en-3-one oxime derivatives, pharmaceutical compositions containing same, and preparation method |
| 04/13/2011 | EP2307420A1 Nalmefene di-ester prodrugs |
| 04/13/2011 | EP2307417A2 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine compounds |
| 04/13/2011 | EP2307416A2 Substituted tricyclic derivatives against neurodegenerative diseases |
| 04/13/2011 | EP2307414A2 Pi3k isoform selective inhibitors |
| 04/13/2011 | EP2307410A1 Aza-beta-carbolines and methods of using same |
| 04/13/2011 | EP2307408A1 Azabicyclooctyl-quinazolone derivatives useful as nicotinic acetylcholine receptor modulators |
| 04/13/2011 | EP2307396A1 Renin inhibitors and method of use thereof |
| 04/13/2011 | EP2307394A2 Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist and pharmaceutical compositions containing the same |
| 04/13/2011 | EP2307389A1 Dibenzothiazepine derivatives and use thereof |
| 04/13/2011 | EP2307374A1 Piperazin-1-yl-trifluoromethyl-substituted-pyridines as fast dissociating dopamine 2 receptor antagonists |
| 04/13/2011 | EP2307058A2 Glycerophospholipids for the improvement of cognitive functions |
| 04/13/2011 | EP2307044A1 Orally administrable dosage forms comprising angiogenin and uses thereof |
| 04/13/2011 | EP2307042A2 Modulation of the trpv : vps10p-domain receptor system for the treatment of pain |
| 04/13/2011 | EP2307039A2 Opiorphin for use as a psychostimulant agent |
| 04/13/2011 | EP2307035A2 Treatment for epilepsy |
| 04/13/2011 | EP2307021A1 Formulations |
| 04/13/2011 | EP2307020A1 Administration regime for nitrocatechols |
| 04/13/2011 | EP2307019A1 Pharmaceutical compositions comprising gamma secretase modulators |
| 04/13/2011 | EP2307013A1 Pain-relieving compositions of furoxan no donors and uses thereof |
| 04/13/2011 | EP2307011A1 Use of isoindoles for the treatment of neurobehavioral disorders |
| 04/13/2011 | EP2307005A1 Taxifolin derivatives for the prophylaxis and treatment of neurological and psychiatric disorders of the central nervous system |
| 04/13/2011 | EP2307004A1 Novel treatments |
| 04/13/2011 | EP2307000A1 Combination of pilocarpin and methimazol for treating charcot-marietooth disease and related disorders |
| 04/13/2011 | EP2306998A1 Pharmaceutical formulation |
| 04/13/2011 | EP2306979A1 Liposomes capable of effectively binding the beta amyloid peptide |
| 04/13/2011 | EP2306839A1 Gacyclidine formulations |
| 04/13/2011 | EP2094690B1 2-aza-bicyclo[3.1.0]hexane derivatives as orexin receptor antagonists |
| 04/13/2011 | EP1928886B1 Pyridine derivatives and their use in the treatment of psychotic disorders |
| 04/13/2011 | EP1888064B1 Benztropinamine analogs as dopamine uptake inhibitors |